Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-Time Continuous Glucose Monitoring in Capivasertib-Treated HR-Positive, HER2-Negative Breast Cancer
jRCTs042250167Recruiting
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capivasertib in breast cancer (2 arms). Primary endpoint: Accuracy of blood glucose measurements by rt-CGM (Dexcom G7) compared to SMBG. Started Jan 2026; status: recruiting.
02
Drugs
capivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs042250167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs042250167.